{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:30:48Z","timestamp":1781850648112,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Thrombocytopenia due to hypersplenism is a major complication of hepatitis C virus (HCV)-associated cirrhosis. HCV eradication improves these complications in some patients, but the long-term effects of HCV eradication on these complications remain unclear, especially in patients treated with direct acting antivirals (DAAs). The aim was to evaluate long term changes in thrombocytopenia and leucopenia after HCV eradication with DAAs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The present multicenter study retrospectively evaluated changes over 5\u00a0years in thrombocytopenia and leukocytopenia, as well as changes in liver fibrosis markers and spleen size, in 115 patients with HCV-cirrhosis treated with DAAs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thrombocytopenia and leukocytopenia were improved 4\u00a0weeks after DAA administration, with thrombocytopenia show further gradual improvement over the next year. Fib-4 index was markedly reduced 1\u00a0year after DAA, followed by subsequent gradual reduction over the next 4\u00a0years. Spleen size showed gradual annual reductions, with patients experiencing spleen size reduction characterized at baseline by bilirubinemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Rapid DAA-associated HCV eradication might lead to rapid disappearance of liver inflammation and bone marrow suppression due to HCV infection. HCV eradication may gradually improve portal hypertension, reducing spleen size.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-02829-w","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T06:01:58Z","timestamp":1684994518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals"],"prefix":"10.1186","volume":"23","author":[{"given":"Kazuto","family":"Tajiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Kashii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Tokimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Muraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Minemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"1","key":"2829_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"2829_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2893.2010.01366.x","volume":"18","author":"KS Louie","year":"2011","unstructured":"Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat. 2011;18(1):1\u20137.","journal-title":"J Viral Hepat"},{"issue":"6","key":"2829_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.13317","volume":"37","author":"M Peck-Radosavljevic","year":"2017","unstructured":"Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37(6):778\u201393.","journal-title":"Liver Int"},{"issue":"2","key":"2829_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.14218\/JCTH.2020.00007","volume":"8","author":"S Rawi","year":"2020","unstructured":"Rawi S, Wu GY. Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review. J Clin Transl Hepatol. 2020;8(2):184\u201391.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"2829_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jhep.2009.11.017","volume":"52","author":"CY Dai","year":"2010","unstructured":"Dai CY, Ho CK, Huang JF, Hsieh MY, Hou NJ, Lin ZY, et al. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2010;52(2):160\u20136.","journal-title":"J Hepatol"},{"issue":"5","key":"2829_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303\u201313.","journal-title":"Gastroenterology"},{"issue":"2","key":"2829_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","volume":"156","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Feld JJ. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? Gastroenterology. 2019;156(2):446-60 e2.","journal-title":"Gastroenterology"},{"issue":"6","key":"2829_CR8","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jgh.13252","volume":"31","author":"AJ van der Meer","year":"2016","unstructured":"van der Meer AJ, Maan R, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2016;31(6):1168\u201376.","journal-title":"J Gastroenterol Hepatol"},{"issue":"19","key":"2829_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020156","volume":"99","author":"YC Chen","year":"2020","unstructured":"Chen YC, Tseng CW, Tseng KC. Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. Medicine (Baltimore). 2020;99(19): e20156.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2829_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/hepr.13426","volume":"50","author":"Y Ishizu","year":"2020","unstructured":"Ishizu Y, Ishigami M, Hayashi K, Honda T, Kuzuya T, Ito T, et al. Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2020;50(1):47\u201356.","journal-title":"Hepatol Res"},{"issue":"4","key":"2829_CR11","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/ph3041162","volume":"3","author":"MG Tovey","year":"2010","unstructured":"Tovey MG, Lallemand C. Safety, Tolerability, and Immunogenicity of Interferons. Pharmaceuticals (Basel). 2010;3(4):1162\u201386.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"2829_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/jvh.12731","volume":"24","author":"K Johnson","year":"2017","unstructured":"Johnson K, Green PK, Ioannou GN. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. J Viral Hepat. 2017;24(11):966\u201375.","journal-title":"J Viral Hepat"},{"issue":"3","key":"2829_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D'Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379\u201387.","journal-title":"J Hepatol"},{"issue":"1","key":"2829_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12876-021-01606-x","volume":"21","author":"YC Chen","year":"2021","unstructured":"Chen YC, Ko PH, Lee CC, Tseng CW, Tseng KC. Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy. BMC Gastroenterol. 2021;21(1):30.","journal-title":"BMC Gastroenterol"},{"issue":"Suppl(1)","key":"2829_CR15","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2004.11.015","volume":"42","author":"F Durand","year":"2005","unstructured":"Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(Suppl(1)):S100-7.","journal-title":"J Hepatol"},{"issue":"6","key":"2829_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"3","key":"2829_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.7863\/jum.1999.18.3.231","volume":"18","author":"I De Odorico","year":"1999","unstructured":"De Odorico I, Spaulding KA, Pretorius DH, Lev-Toaff AS, Bailey TB, Nelson TR. Normal splenic volumes estimated using three-dimensional ultrasonography. J Ultrasound Med. 1999;18(3):231\u20136.","journal-title":"J Ultrasound Med"},{"issue":"2","key":"2829_CR18","first-page":"221","volume":"73","author":"A Tanaka","year":"2015","unstructured":"Tanaka A. JSH guidelines for the management of hepatitis C virus infection (version 3). Nihon Rinsho. 2015;73(2):221\u20137.","journal-title":"Nihon Rinsho"},{"issue":"6","key":"2829_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","volume":"17","author":"H Hidaka","year":"2019","unstructured":"Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, et al. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Clin Gastroenterol Hepatol. 2019;17(6):1192\u2013200.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2829_CR20","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1007\/s12325-022-02235-w","volume":"39","author":"ME Orme","year":"2022","unstructured":"Orme ME, Bentley R, Marcella S, Peck-Radosavljevic M, Perard R, Wedemeyer H, et al. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures. Adv Ther. 2022;39(9):4169\u201388.","journal-title":"Adv Ther"},{"issue":"8","key":"2829_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00705-012-1321-z","volume":"157","author":"AR Abou El Azm","year":"2012","unstructured":"Abou El Azm AR, El-Bate H, Abo-Ali L, Mansour N, Ghoraba H, Salem ML. Correlation of viral load with bone marrow and hematological changes in pale patients with chronic hepatitis C virus. Arch Virol. 2012;157(8):1579\u201386.","journal-title":"Arch Virol"},{"issue":"12","key":"2829_CR22","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood.V95.12.3986.012k39_3986_3989","volume":"95","author":"M Radkowski","year":"2000","unstructured":"Radkowski M, Kubicka J, Kisiel E, Cianciara J, Nowicki M, Rakela J, et al. Detection of active hepatitis C virus and hepatitis G virus\/GB virus C replication in bone marrow in human subjects. Blood. 2000;95(12):3986\u20139.","journal-title":"Blood"},{"issue":"5","key":"2829_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1172\/JCI105380","volume":"45","author":"RH Aster","year":"1966","unstructured":"Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of \u201chypersplenic\u201d thrombocytopenia. J Clin Invest. 1966;45(5):645\u201357.","journal-title":"J Clin Invest"},{"issue":"10","key":"2829_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010087","volume":"97","author":"C He","year":"2018","unstructured":"He C, Liu X, Peng W, Li C, Wen TF. Evaluation the efficacy and safety of simultaneous splenectomy in liver transplantation patients: A meta-analysis. Medicine (Baltimore). 2018;97(10): e0087.","journal-title":"Medicine (Baltimore)"},{"key":"2829_CR25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2147\/OTT.S87580","volume":"8","author":"W Li","year":"2015","unstructured":"Li W, Shen SQ, Wu SM, Chen ZB, Hu C, Yan RC. Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis. Onco Targets Ther. 2015;8:2129\u201337.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2829_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/00042737-199604000-00017","volume":"8","author":"R Jalan","year":"1996","unstructured":"Jalan R, Redhead DN, Allan PL, Hayes PC. Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol. 1996;8(4):381\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2829_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S0168-8278(99)80071-3","volume":"30","author":"M Gschwantler","year":"1999","unstructured":"Gschwantler M, Vavrik J, Gebauer A, Kriwanek S, Schrutka-Kolbl C, Fleischer J, et al. Course of platelet counts in cirrhotic patients after implantation of a transjugular intrahepatic portosystemic shunt\u2013a prospective, controlled study. J Hepatol. 1999;30(2):254\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"2829_CR28","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/0016-5085(91)90293-T","volume":"100","author":"IH Borel Rinkes","year":"1991","unstructured":"Borel Rinkes IH, Van der Hoop AG, Hesselink EJ, Metselaar H, De Rave S, Zonderland HM, et al. Does auxiliary heterotopic liver transplantation reverse hypersplenism and portal hypertension? Gastroenterology. 1991;100(4):1126\u20138.","journal-title":"Gastroenterology"},{"key":"2829_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/2193-1801-2-374","volume":"2","author":"M Ishigami","year":"2013","unstructured":"Ishigami M, Ishizu Y, Onishi Y, Kamei H, Kiuchi T, Itoh A, et al. Long-term dynamics of hematological data and spleen volume in cirrhotic patients after liver transplantation-various dynamics depending on etiology. Springerplus. 2013;2:374.","journal-title":"Springerplus"},{"issue":"5","key":"2829_CR30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10620-019-05886-y","volume":"65","author":"R Huang","year":"2020","unstructured":"Huang R, Rao H, Yang M, Gao Y, Wang J, Jin Q, et al. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy. Dig Dis Sci. 2020;65(5):1491\u2013500.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"2829_CR31","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jvh.13558","volume":"28","author":"Q Kang","year":"2021","unstructured":"Kang Q, Xu J, Luo H, Tan N, Chen H, Cheng R, et al. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication. J Viral Hepat. 2021;28(9):1284\u201392.","journal-title":"J Viral Hepat"},{"issue":"1","key":"2829_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","volume":"16","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(1):27-38 e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2829_CR33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/liv.12240","volume":"33","author":"S Bota","year":"2013","unstructured":"Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33(8):1138\u201347.","journal-title":"Liver Int"},{"issue":"11","key":"2829_CR34","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1111\/jvh.13587","volume":"28","author":"V Knop","year":"2021","unstructured":"Knop V, Hoppe D, Vermehren J, Troetschler S, Herrmann E, Vermehren A, et al. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study. J Viral Hepat. 2021;28(11):1604\u201313.","journal-title":"J Viral Hepat"},{"issue":"3","key":"2829_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3350\/cmh.2015.0050","volume":"22","author":"SJ Lee","year":"2016","unstructured":"Lee SJ, Cho YK, Na SY, Choi EK, Boo SJ, Jeong SU, et al. Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy. Clin Mol Hepatol. 2016;22(3):390\u20135.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2829_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","volume":"151","author":"V Di Marco","year":"2016","unstructured":"Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. Gastroenterology. 2016;151(1):130-9 e2.","journal-title":"Gastroenterology"},{"issue":"4","key":"2829_CR37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65(4):692\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"2829_CR38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","volume":"72","author":"M Pons","year":"2020","unstructured":"Pons M, Rodriguez-Tajes S, Esteban JI, Marino Z, Vargas V, Lens S, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol. 2020;72(3):472\u201380.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02829-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02829-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02829-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T06:03:09Z","timestamp":1684994589000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02829-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2829"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02829-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee, University of Toyama. The requirement for informed consent was waived by the Ethics Committee of University of Toyama because of the retrospective and non-interventional nature of the study. Instead, opt-out consent was performed. The principles of the Declaration of Helsinki were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KT received research fee from Abbvie GK and remaining other authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}